Clinical Trials Logo

Pneumococcal Vaccines clinical trials

View clinical trials related to Pneumococcal Vaccines.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06271681 Not yet recruiting - Immunosuppression Clinical Trials

Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans

Start date: May 1, 2024
Phase: Phase 4
Study type: Interventional

The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster series of 15-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine 8 weeks later. Immune response will be assessed by opsonophagocytic assay reactivity and IgG Geometric mean concentration changes.

NCT ID: NCT05721456 Not yet recruiting - Clinical trials for Pneumococcal Vaccines

Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil.

Start date: August 28, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this phase III study is to demonstrate immunologic non-inferiority in terms of proportion of individuals with antibody concentration ≥0.2 µg/mL (by modified 22F-inhibition enzyme-linked immunosorbent assay, ELISA) or in terms of ELISA geometric mean concentrations (GMC) of serotype-specific IgG, of 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM, hereby indicated as PCV12), containing the serotypes 1, 4, 5, 6B, 7F, 9V, 14, and 23F conjugated with non-typeable Haemophilus influenzae protein D, 19F conjugated with TD, 18C conjugated with TT, and 6A and 19A conjugated with CRM197, and to assess its safety in the population of infants vaccinated from 2 months of age with a primary regimen of 2 or 3 doses plus a booster administered at one year of life.